The Role of Tobacco in The Development of Nicotine Palatine Leukoplakia

Nicotine, the principal alkaloid in tobacco leaves, constitutes approximately 95% of all alkaloids in cigarettes and is the primary agent responsible for tobacco addiction. Tobacco products vary in nicotine content, with pipe tobacco containing similar levels to cigarettes, while cigars and chewing tobacco contain less. Nicotine is rapidly absorbed depending on its pH and the route of exposure, accumulating in the brain, saliva, gastric juice, liver, lungs, kidneys, and crossing the placental and mammary barriers. The metabolic rate of nicotine, influenced by factors such as age, gender, nutrition, pregnancy, and CYP2A6 genetic polymorphism, determines the intensity of addiction and the success of cessation attempts. Chronic exposure to tobacco smoke introduces thousands of toxic compounds that affect cardiovascular, respiratory, and immune systems. Nicotine dependence manifests through withdrawal syndrome, increased tolerance, persistent desire for tobacco use, and continued consumption despite harmful effects. Early identification of nicotine addiction using standardized diagnostic criteria and assessment tools, such as the Fagerström Test, is crucial for effective interventions. This study examines the role of tobacco in the development of nicotine-induced palatine leukoplakia, emphasizing pathophysiological mechanisms, systemic distribution of nicotine, and clinical implications for prevention and treatment.